Voyce, Hamilton Health Sciences and OBIO® Showcase Breakthrough in Patient Care Through Language Access Technology

Partnership exemplifies the power of technology-enabled accessible language services in healthcare, ensuring patients receive care in their language of choice.

April 23, 2024 (Hamilton, ON) – In a significant advancement for patient care, Voyce, a leading provider of real-time medical interpretation services, together with Hamilton Health Sciences (HHS), is proud to announce their successful collaboration in enhancing communication for non-English speaking patients.

Voyce was adopted with the support of OBIO’s Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence after a successful evaluation was completed through the Early Adopter Health Network (EAHN™) program. These interpretation services ensure that every patient, regardless of their native language, receives the care and understanding they deserve.

OBIO® evaluates new technologies through EAHN™ and implements successful solutions using critical technologies through the LSCTC Centre of Excellence. EAHN™ is supported by the Government of Canada through the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), and LSCTC is supported by the Government of Ontario.

“OBIO® continues to provide vital supports for our health tech leaders that enable innovators to advance new and groundbreaking healthcare technologies. Strengthening our healthcare institutions and healthcare technologies will lead to better outcomes and care for Canadians,” said the Honourable Filomena Tassi, Minister responsible for the Federal Economic Development Agency for Southern Ontario.

“Our government is proud to support the development and commercialization of critical technologies in our growing life sciences sector,” said Vic Fedeli, Minister of Economic Development, Job Creation and Trade. “Thank you, Voyce and Hamilton Health Sciences, for your leadership in implementing cutting-edge medical technology to enhance patient care and for producing life-saving solutions celebrated across the world.”

Through Voyce’s state-of-the-art platform that integrates 5G technology, HHS will be able to offer remote video and audio interpretation services in over 240 languages, including sign language, to support effective communication between patients and their care providers.

“The availability of Voyce’s platform is a huge step forward in helping Hamilton Health Sciences provide better access to healthcare for all patients. The ease of access to hundreds of languages and sign language in near real-time is a major enabler for the exchange of vital health information between patients and their care providers,” shared Ted Scott, Vice President of Innovation and Partnerships at Hamilton Health Sciences. “Voyce ensures that everyone in the room is on the same page when it comes to understanding a patient’s needs and plan of care. The platform is also being extended into the hospital’s research and education activities so that we can better understand the healthcare needs of our non-English speaking community. We are thankful to OBIO® for helping us accelerate the adoption and implementation of this technology at HHS.”

This partnership, facilitated by the EAHN™ and LSCTC programs, fosters the adoption and evaluation of new health technologies across Canada, and marks a pivotal step in deploying technology solutions that cater to Canada’s diverse linguistic landscape.

“The adoption of the Voyce platform exemplifies the power of innovation in bridging language barriers and ensuring equitable access to healthcare for everyone,” said Dr. Maura Campbell, President and CEO of OBIO®. “By supporting the integration of Voyce’s real-time interpretation services at Hamilton Health Sciences, we are fostering a more inclusive healthcare system in Ontario.”

The importance of this initiative cannot be overstated; it offers profound benefits including improved patient comprehension, satisfaction, and outcomes. At the click of a button, patients, nurses, and doctors can access a medically qualified human interpreter through Voyce devices within HHS’ facilities.

“By prioritizing patient-centered language and cultural competence, our interpreters play an integral role in upholding our partners’ commitment to providing equitable and inclusive healthcare services,” said Andrew Royce, CEO of Voyce. “Our commitment to quality education supports our partnership with Hamilton Health Sciences on our mutual goal of enhancing patient care and serving as a model for excellence in healthcare interpretation across Ontario.”

By enabling language-accessible care, this initiative not only respects but also embraces the Hamilton region’s diverse patient population of 2.3 million, ensuring that every patient feels heard, understood, and valued.

“We aim to have Voyce in all patient-facing areas across HHS,” said Tim Dietrich, Vice President, Quality and Performance at Hamilton Health Sciences. “It is currently available in all in-patient, emergency and diagnostic imaging areas, and we are planning for implementation in all ambulatory settings. So far, our teams and patients have utilized Voyce more than 9,000 times accessing 85 distinct languages and dialects.”

This partnership between Voyce and HHS, championed by OBIO’s EAHN™ and LSCTC programs, represents a step forward for healthcare inclusivity in Canada. By prioritizing effective communication, this initiative ensures that everyone, regardless of language, receives the quality care they need and deserve.

About Hamilton Health Sciences

Hamilton Health Sciences (HHS) is a community of 18,000 staff, physicians, researchers and volunteers that proudly serves southwestern Ontario residents. HHS also provides specialized, advanced care to people from across the province.

It is the only hospital in Ontario that cares for all ages, from pre-birth to end-of-life. HHS offers world-leading expertise in many areas, including cardiac and stroke care, cancer care, palliative care and pediatrics.

About OBIO® 

Founded in 2009, OBIO®, a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization, is prioritizing the evaluation of new technologies through their Early Adopter Health Network (EAHN™). OBIO® is engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies, positioning Canada as a leader in the international marketplace.

For more information, please visit obio.ca and follow OBIO® on LinkedIn and X.

About Voyce

Voyce is a technology-driven company deeply committed to helping people in need facing language barriers, enabling them to communicate and get help when they need it the most. Voyce’s professional and qualified language interpreters provide medical interpretation across a variety of technology and telehealth platforms in 240+ languages and dialects, including American Sign Language. Across the United States, Canada, the United Kingdom, and globally, Voyce supports millions of conversations each year, giving patients and providers the confidence to communicate effectively.

For more information visit www.voyceglobal.com and follow Voyce on LinkedIn.

Contacts:

Wendy Stewart
Communications Advisor
Hamilton Health Sciences
stewartwen@hhsc.ca

Liam Afonso
Creative Director
Voyce
liam.afonso@voyceglobal.com 

Doriane Rey
Manager, Marketing & Events
OBIO®
dorianerey@obio.ca

Edward Hutchinson
Press Secretary
Office of the Minister responsible for the Federal Economic Development Agency for Southern Ontario
edward.hutchinson@feddevontario.gc.ca

Morphocell Technologies announces completion of US$40 Million Series A financing

Morphocell Technologies Inc., a Montreal-based biotechnology company in the cell therapy space, recently announced the closure of a US$40 million Series A funding round. The funding is set to fuel the company’s groundbreaking journey towards a first-in-human clinical trial of the first cell therapy issued from its tissue engineering platform, aimed at transforming liver disease treatment globally.

Morphocell Technologies is an alumnus of our CAAP® program and presented at the OBIO® Investment Summit.

Rocket Doctor selected for the inaugural cohort of the Google for Startups Accelerator

Rocket Doctor, a technology-driven digital health platform and marketplace that empowers healthcare providers to break down the barriers that prevent patients from accessing care, has been selected for the inaugural cohort of the Google for Startups Accelerator: AI First North America. The program will provide 10 weeks of hands-on mentorship and technical project support to start-ups using AI in their core service or product. Selected start-ups will collaborate with a cohort of top peer founders and engage with leaders across Google.

Rocket Doctor is an alumnus of our BDSP™ and CAAP® programs, presented at the OBIO® Investment Summit, and is a beneficiary of our Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence.

HDAX Therapeutics and Noa Therapeutics' CEOs selected among the 2024 Termeer Fellows

The Termeer Fellowship Program recently announced the class of 2024 Termeer Fellows – a group of fifteen visionary leaders who are passionate about transforming patient care through innovations. The fellows will receive leadership programming, mentorship, and access to a network of industry leaders.

 Congratulations to the selected leaders! Shout-out to Nabanita Nawar, CEO and Co-founder, HDAX Therapeutics and Carla Spina, CEO and Co-founder, Noa Therapeutics!

HDAX Therapeutics and Noa Therapeutics are OBIO® members and alumni of our BDSP™ and WiHI programs.

Hyivy Health featured in the Globe and Mail

Read this story published in the Globe and Mail on the femtech companies and the important work they are doing to tackle gender health gaps and shift the focus on women’s health. We are elated to see Rachel Bartholomew, Founder and CEO, Hyivy Health and other amazing women founders recognized for the tremendous impact they are making in women’s health in this article.

Hyivy Health is an alumnus of our BDSP™, CAAP®, EAHN™ and WiHI programs, and presented at the OBIO® Investment Summit.

16Bit receives FDA De Novo marketing authorization for Rho™

16 Bit Inc., a software medical device company, recently announced that the U.S. Food and Drug Administration (FDA) has granted a De Novo marketing authorization for Rho™, an AI-enabled software device aimed at improving a known care gap in osteoporosis screening. Rho received Breakthrough Device designation by the FDA in March 2021, signifying the first FDA-authorized radiology software for opportunistic evaluation of low bone mineral density (BMD).

16Bit is an alumnus of our BDSP™ and H2BB™ programs, presented at the OBIO® Investment Summit, and is a part of our Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence technology adoption stream.

CHEO selects PolyUnity for 3D Printing Solution

April 11, 2024 (Ottawa, ON) – Following a successful evaluation held in 2022-2023 on how a digital inventory and 3D printing solution could help solve supply chain issues, CHEO is committing to a five-year agreement with PolyUnity Tech to bring Additive Manufacturing capabilities – otherwise known as 3D printing solutions – to pediatric healthcare in Ontario. The evaluation was supported through OBIO’s Early Adopter Health Network (EAHN™) and resulted in more than 200 new innovations, 1,281 products delivered, and 460 pieces of equipment repaired and returned to service, leading to a successful adoption of the solution. OBIO’s EAHN™ program is supported by the Government of Canada through the Federal Economic Development Agency for Southern Ontario (FedDev Ontario).

With supply chain shortages, delays or difficulty in obtaining unique replacement parts, CHEO is exploring new services to expand access to innovative and specialized products. Over the past few years, the CHEO Research Institute collaborated with PolyUnity to better understand how 3D printing could be used in a healthcare setting, with the goal of reducing costs and downtime of equipment.

PolyUnity is at the forefront of bringing Additive Manufacturing as a Service (AMaaS) solutions and its associated benefits to the healthcare sector. Additive manufacturing utilizes a computer-controlled process to create 3D objects by depositing materials, typically layer by layer. By harnessing AMaaS, healthcare organizations can leverage rapid and innovative product solutions to drive operational efficiencies, reduce costs, and enhance overall patient outcomes. AMaaS empowers healthcare professionals such as clinical engineers, doctors, nurses, physiotherapists, and researchers to swiftly transform problems into prototypes and useful products.

Through this agreement, CHEO will continue to work with PolyUnity to leverage its technology, saving costs and creating operational efficiencies while avoiding complex procurement processes along the way.

QUOTES:

“OBIO® is growing the Canadian-made health technologies that are making a difference across Canada. OBIO’s Early Adopter Health Network (EAHN™) is supporting innovators as they find solutions to the challenges facing our health care system to ensure Canadians are getting the best quality care available.” —The Honourable Filomena Tassi, Minister responsible for the Federal Economic Development Agency for Southern Ontario.

“At CHEO, we know that innovation is part of how we constantly improve outcomes of care for children, youth and families. This new agreement with PolyUnity highlights how by working collaboratively with the business and investment communities to explore and validate new technologies can help us bring promising new solutions into healthcare.” —Dr. Jason Berman, Chief Executive Officer and Scientific Director, CHEO Research Institute, and Vice-President Research, CHEO.

“It is the impact of the great collaborative work we do with our healthcare partners that matters most. Creating innovative solutions for supply chain issues and delivering replacement parts quickly for organizations like CHEO has a direct impact on patients. And this work is especially meaningful to us at PolyUnity.” —Mark Gillingham, President, PolyUnity Tech Inc.

“Our healthcare organizations are continuously asked do more with less. And this is why innovation becomes critical to delivering value-based healthcare services. We’re so proud of the 200+ innovative products created in collaboration with CHEO’s team members and are excited to continue creating more solutions together.” —Jacqueline Lee, CEO, PolyUnity Tech Inc.

“Our goal is to help innovative companies like PolyUnity get into new markets and this is exactly what our EAHN™ program was designed to do. We are thrilled to be the first to support the adoption of PolyUnity’s game-changing technology by Ontario healthcare organizations.” —Dr. Maura Campbell, President and CEO of OBIO®.

About CHEO

Dedicated to the best life for every child and youth, CHEO is a global leader in pediatric health care and research. Based in Ottawa, CHEO includes a hospital, children’s treatment centre, school and research institute, with satellite services located throughout Eastern Ontario. CHEO provides excellence in complex pediatric care, research and education. We are committed to partnering with families and the community to provide exceptional care — where, when and how it is needed. Every year, CHEO helps more than 500,000 children and youth from Eastern Ontario, western Quebec, Nunavut and Northern Ontario.

About PolyUnity Tech Inc.

PolyUnity is a Canadian healthcare technology company with a driving purpose to “Improve Healthcare.” Its mission is to work with healthcare organizations and provide 3D printing applications to improve operational efficiencies, reduce costs, and improve patient experiences. PolyUnity provides a fully managed Additive Manufacturing as a Service (AMaaS) solution that includes a digital marketplace platform to efficiently access digital design services and a growing library of 3D printable products and applications that are specific to healthcare organizations. All print production and delivery logistics are also managed by PolyUnity. The solution significantly reduces the cost and complexity of traditional healthcare procurement, builds supply chain resiliency, and reduces its carbon footprint. It enables healthcare providers and their networks to design, access, and produce what they need on demand.

Learn more at www.polyunity.com and connect with us on LinkedIn, Facebook, & Instagram.

About OBIO®

Founded in 2009, OBIO® is a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization, is prioritizing the evaluation of new technologies through its Early Adopter Health Network (EAHN™). OBIO® is engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies, positioning Canada as a leader in the international marketplace.

For more information, please visit OBIO.ca and follow us on LinkedIn and X.

About FedDev Ontario

For 14 years, the Government of Canada, through FedDev Ontario, has worked to advance and diversify the southern Ontario economy through funding opportunities and business services that support innovation, growth and job creation in Canada’s most populous region. The Agency has delivered impressive results, which can be seen in southern Ontario businesses that are creating innovative technologies, improving productivity, growing revenues, creating jobs, and in the economic advancement of communities across the region. Learn more about the impacts the Agency is having in southern Ontario by exploring our pivotal projects, our Southern Ontario Spotlight, and FedDev Ontario’s Twitter, Facebook, Instagram and LinkedIn.

Media Contacts:

Jennifer Ruff
Director of Communications
CHEO Research Institute
jruff@cheo.on.ca

Mark Gillingham
President
PolyUnity Tech Inc.‍
mark@polyunity.com

Doriane Rey
Manager, Marketing & Events
OBIO®
dorianerey@obio.ca

Edward Hutchinson
Press Secretary
Office of the Minister responsible for the Federal Economic Development Agency for Southern Ontario
edward.hutchinson@feddevontario.gc.ca

DIGITAL and Swift Medical announce pioneering co-investment in AI for enhanced wound care

Swift Medical announced a strategic co-investment from DIGITAL, Canada’s Global Innovation Cluster for digital technologies, as a landmark move to push the boundaries of healthcare innovation. This collaboration is set to revolutionize the way wound care is delivered, utilizing artificial intelligence (AI) to forge significant advancements in patient outcomes and equity in treatment. The partnership will focus on the deployment of Swift Medical’s cutting-edge AI technologies designed to standardize and improve wound care.

Swift Medical is an OBIO® member and an alumnus of our BDSP™ and CAAP® programs.

ProteinQure announces a breakthrough therapeutic in the fight against Triple-Negative Breast Cancer

ProteinQure, the leading start-up in the computational design of peptide drugs, recently announced a significant breakthrough in the fight against Triple-Negative Breast Cancer. The novel Peptide Drug Conjugate, designed by ProteinQure, demonstrated exceptional efficacy in a comprehensive suite of Patient-Derived Xenograft (PDX) models. The experiments were conducted in the lab of Dr. David Cescon at the Princess Margaret Cancer Centre/University Health Network, one of the world's top five cancer research centres.

ProteinQure is an OBIO® member and an alumnus of our BDSP™, CAAP® and WiHI programs.

mDETECT featured in the National Post

mDETECT is among the four companies selected for BioCreate, the program funded by Ontario Genomics, a non-profit organization funded by the Government of Ontario and FedDev Ontario. mDetect has developed a blood test that detects six common cancers and provides doctors with information about how well a patient has responded to treatment.

mDETECT is an OBIO® member, an alumnus of our WiHI program, and presented at the OBIO® Investment Summit.

Conavi and Titan Medical merge to help ignite widespread adoption of next-generation Novasight Hybrid intravascular imaging platform

Conavi Medical’s reverse merger with Titan Medical, which is expected to close in July 2024, and concurrent financing are anticipated to cultivate an investor network to help fund the expansion of the Novasight Hybrid System, a breakthrough imaging platform for use by interventional cardiologists during common minimally invasive heart procedures.

Conavi Medical is an OBIO® member and alumnus of our BDSP™, CAAP® and WiHI programs, and presented at the OBIO® Investment Summit.

Ontario biotech start-ups get government funding and business support

Four new start-ups have been welcomed into BioCreate, Ontario Genomics’ $11.6-million accelerator program providing financial and business support to biotechnology companies that are creating game-changing solutions in the health, food and agriculture, and cleantech industries. BioCreate is funded by Ontario Genomics and a Government of Canada investment of over $5.6 million, through the Federal Economic Development Agency for Southern Ontario (FedDev Ontario).

The program connects highly vetted companies with $150,000 in funding, 18 months of business mentorship, access to critical infrastructure to scale up their products and an opportunity to pitch to investors for further funding.

Congratulations to the selected companies - AuX Labs, Genuine Taste, mDETECT and Scispot! Shout-out to OBIO-affiliated companies, SciSpot and mDETECT!

Flosonics Medical secures $20 million USD in Series C funding

Flosonics Medical, a leader in wearable medical ultrasound, announced its Series C financing, raising $20 million USD. The round was led by New Leaf Venture Partners, with participation from previous investors Arboretum Ventures, Genesys Capital and iGan Partners. This new funding will support Flosonics as the company continues to innovate and drive market adoption of FloPatch, a first-in-class wearable Doppler ultrasound for hemodynamic assessments.

Flosonics Medical is an OBIO® member, an alumnus of our BDSP™, CAAP®, EAHN™, HealthMINT™ and WiHI programs, and presented at the OBIO® Investment Summit.

Through OBIO’s EAHN™, Trexo Plus Robotic Walker Enables Children with Physical Disabilities to Achieve Personalized Rehabilitation

March 26, 2024 (Toronto, ON) – An effective physical therapy for children with injuries or disabilities affecting their motor skills requires an innovative solution that can build muscle memory and stimulate neuroplasticity. There are currently no effective interventions known to improve motor function for children with severe disabilities. To address this challenge, Ontario-based health technology company Trexo Robotics developed Trexo Plus, a robotic walking device for injured or disabled children’s rehabilitation. Last year, Trexo joined forces with OBIO’s Early Adopter Health Network (EAHN™) and the Innovation and Business Intelligence team at Alberta Health Services (AHS) to assess the viability of Trexo Plus in a clinical setting.

The EAHN™ program was a catalyst behind this evaluation, with the goal of expanding the reach of health tech companies in Ontario and supporting the positioning of Canada as a leader in innovative health tech.

Final findings indicated that children with disabilities who used Trexo Plus met their rehabilitation goals. They had high performance and satisfaction scores, achieved their health-related objectives and were able to access the best available care, leading their families to express a keen interest in the technology.

“This device was created through an iterative process with therapists, other healthcare professionals and families,” said Manmeet Maggu, co-founder and CEO of Trexo Robotics. “The device has evolved, offering more features and benefits. Our mission from day one has been to reach and benefit as many children as possible.”

“This study enabled us to explore implementation of a cutting-edge intervention and provide equitable access to robotic walking for children with severe mobility impairments,” said Dr. Elizabeth Condliffe, University of Calgary and Alberta Children’s Hospital, and the evaluation’s Lead Study Investigator. “It has generated overwhelming interest in Calgary.”

“This study highlighted how the transformative potential of health technologies can improve the quality of life for children with disabilities,” said Dr. Maura Campbell, President and CEO of OBIO®. “Through the EAHN™ program, we continue to accelerate the adoption of innovative health technologies by providing Ontario start-ups access to the Canadian healthcare market.”

About OBIO®

Founded in 2009, OBIO®, a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization, is prioritizing the evaluation of new technologies through its Early Adopter Health Network (EAHN™). OBIO® is engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies, positioning Canada as a leader in the international marketplace. For more information, please visit obio.ca and follow OBIO® on LinkedIn and X (formerly Twitter).

Contact:
Bibaswan Ghoshal
Senior Director, Technology Adoption
bibaswanghoshal@obio.ca
416-848-6839 x 125

About Trexo Robotics

Trexo Robotics is a leading innovator in robotic gait trainers, dedicated to enhancing the lives of individuals with physical challenges. Founded on the principle that everyone deserves the opportunity to walk, Trexo develops robotic gait trainers to empower children to experience the benefits of walking.

Contact:
Jennifer Horowitz
Head of Marketing
jh@trexorobotics.com
562-784-7711

Tenomix secures oversubscribed $2.1M, all-Canadian financing round to advance cancer staging

Tenomix, an image-guided diagnostic company based out of Western University’s BioNext Medtech Incubator, recently celebrated a significant milestone with an oversubscribed all-Canadian $2.14M funding round. This funding round includes contributions from FACIT, the Ontario Centre of Innovation’s Life Science Innovation Fund, Phoenix Fire Fund (part of the Archangel Network of Funds), OBIO’s Women in Health Initiative Seed Program, and individual angel investors.

The recent funding will fuel Tenomix’s ambitions to expand its technical team, accelerate their IP applications, and complete validation studies with leading North American hospitals and health centres. Achieving those milestones will pave the way for FDA and Health Canada clearance, furthering the impact on patient care and health systems

We are happy to support Tenomix through OBIO’s Women in Health Initiative Seed Program! Tenomix is an OBIO® member and an alumnus of our BDSP™ and HealthMINT™ programs.

Quthero secures $500,000 investment boost from the Ontario Centre of Innovation

Quthero, a pioneering biotech company renowned for its unique Q-peptide platform technology, recently announced the successful acquisition of $500,000 in investment funding from the Ontario Centre of Innovation's (OCI) Life Science Innovation Fund. This is in addition to a co-investment of $850,000 for a total round size of $1,350,000.

Quthero is an OBIO® member, an alumnus of our BDSP™, CAAP®, HealthMINT™ programs, and presented at the OBIO® Investment Summit.

Noa Therapeutics secures pre-Seed financing to transform the treatment of inflammatory disease

Noa Therapeutics, a preclinical stage biotech company with a portfolio of novel trimodal therapeutics to address inflammatory barrier diseases, secured an oversubscribed pre-Seed financing round. The round was led by UCeed, with participation inclusive of Ontario Centre of Innovation Life Science Innovation Fund, Archangel Network's StarForge and Phoenix Fire funds, Golden Triangle Angel Network, Angel One Investor Network, and NorthSpring Capital Partners. The financing round is inclusive of 58% of investment diligence led by women and 27% direct dilutive investment by women.

Noa Therapeutics is an OBIO® member, an alumnus of our BDSP™, H2BB™ and WiHI programs, and presented at the OBIO® Investment Summit.

Fusion Pharmaceuticals to be acquired by AstraZeneca, accelerating development of next-generation radioconjugates to treat cancer

Fusion Pharmaceuticals, a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, recently announced entering into a definitive agreement to be acquired by AstraZeneca. The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.

Fusion Pharmaceuticals is an OBIO® member and an alumnus of our BDSP™ program.

Domain Therapeutics and Chime Biologics join forces to advance novel anti-CCR8 antibody for cancer immunotherapy

Domain Therapeutics, a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs) and Chime Biologics, a leading Contract Development and Manufacturing Organization (CDMO) that enables its partners’ success in biologics, announced the signing of a manufacturing service agreement for the production of Domain’s best-in-class Treg depleting anti-CCR8 antibody candidate, DT-7012. This phase of manufacturing aims to deliver an effective therapeutic for cancer patients worldwide.

Domain Therapeutics is an OBIO® member and presented at the OBIO® Investment Summit.

Cosm Medical achieves FDA clearance for Gynethotics™ Pessaries, pioneering the future of personalized pelvic care

Cosm Medical achieved FDA clearance for Gynethotics™ Pessaries, marking it as the first personalized pessary available to patients. This milestone follows a recent Health Canada clearance and marks a significant advancement in pelvic care, emphasizing Cosm’s commitment to enhancing patient outcomes and revolutionizing treatment options for women worldwide.

Cosm Medical is an OBIO® member, an alumnus of our BDSP™, CAAP®, H2BB™, HealthMINT™ and WiHI programs, and presented at the OBIO® Investment Summit.